27th October 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

J&J receives US FDA nod for blood cancer therapy

The US FDA has approved Johnson and Johnsons’ drug named Teclistamab (brand name Tecvayli) for the treatment of Multiple Myeloma in Adults, giving the patients a second option of treatment for the almost incurable blood cancer.

Zydus's Micafungin for injection gets final approval from US FDA

The US regulatory authority has given final approval to Zydus to manufacture and market Micafungin for injection, 50 mg/vial and 100 mg/vial, single-dose vials. The drug is indicated for the treatment of a variety of fungal infections and also to prevent fungal infections in patients undergoing a stem cell transplant.

Pharma stock tanks 14% in three days, expected to have a rise of up to 39%

On Tuesday, Laurus Labs shares rolled down by 5.56% in early trades and were quoting at ₹453 levels as compared to ₹525 levels on October 21, 2022. The current share price indicates an overall fall of 13.71% during the past three sessions.

Hyderabad Pharma City, mega pharma park to be launched soon

The Hyderabad Pharma City (HPC), an ambitious project by the Telangana Government is expected to be launched soon. The cluster has been identified as the NIMZ (National Investment and Manufacturing Zone) by the Government of India, Center of Excellence, and is expected to attract investments worth billions of Dollars.

CDSCO panel asks Synokem pharma about Phase 3 CT of Naftifine Cream

The SEC (Subject Expert committee) under the CDSCO has asked the drugmaker Synokem Pharma to submit enough rationale for the proposed un-blinding of randomization and interim analysis of data before the committee concerning its Phase III clinical trials with the drug Naftifine HCl Cream 2%w/w.

US regulatory body issues import alert on Glenmark's Pharma Baddi plant

The drugmaker Glenmark Pharmaceuticals declared on wednesday that US FDA has put an import alert on its manufacturing plant at baddi, Himachal Pradesh. The drugs manufactured at the said facility can now be detained without any physical examination.

Milla Pharma of Alter Pharma Group announces first paragraph 4 filing and acceptance by FDA

Milla Pharma which is a subsidiary of the Alter Pharma Group announced that it applied for a Paragraph IV Certification to US regulatory authority on July 20th, 2022 and received an Acknowledgement Letter and Receipt for the same on August 31st, 2022. 

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?